APO-SALVENT 5MG/ML SOLUTION

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Kupi sada

Svojstava lijeka Svojstava lijeka (SPC)
16-03-2020

Aktivni sastojci:

SALBUTAMOL (SALBUTAMOL SULFATE)

Dostupno od:

APOTEX INC

ATC koda:

R03AC02

INN (International ime):

SALBUTAMOL

Doziranje:

5MG

Farmaceutski oblik:

SOLUTION

Sastav:

SALBUTAMOL (SALBUTAMOL SULFATE) 5MG

Administracija rute:

INHALATION

Jedinice u paketu:

10ML

Tip recepta:

Prescription

Područje terapije:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0108887006; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

1993-08-11

Svojstava lijeka

                                _Page 1 of 32_
PRODUCT MONOGRAPH
PR
APO-SALVENT RESPIRATOR SOLUTIONS
(SALBUTAMOL SULFATE SOLUTIONS BP)
PR
APO-SALVENT RESPIRATOR SOLUTION 50 MG IN 10 ML (5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 1.25 MG IN 2.5 ML (0.5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 2.5 MG IN 2.5 ML (1 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 5.0 MG IN 2.5 ML (2 MG/ML SALBUTAMOL)
BRONCHODILATOR,
Β
2
-ADRENERGIC STIMULANT
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
March 16, 2020
CONTROL # 236795
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................................................
8
DOSAGE AND ADMINISTRATION
........................................................................................................................
10
OVERDOSAGE
..........................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Svojstava lijeka Svojstava lijeka francuski 16-03-2020

Upozorenja za pretraživanje vezana za ovaj proizvod